Publications

Sort publications on year

  • Biometry and database analysis

    Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

    HARROW B, FAGNANI F, NEVORET C, TRUONG-THANH XM, DE ZÉLICOURT M, DE MESTIER L.

    Adv Ther ; 2022;39:1754-1771

  • Biometry and database analysis

    Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

    WEIL-OLIVIER C, TAHA MK, BOUEE S, EMERY C, LONCLE-PROVOT V, NACHBAUR G, BECK E, PRIBIL C.

    Human Vaccines & Immunotherapeutics ; 2022;18(1):2021764

  • Biometry and database analysis

    Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis.

    NEUZILLET C, EMERY C, TEISSIER C, BOUEE S, LIEVRE A.

    Lancet Reg Health Eur ; 2022;15:100324

  • Biometry and database analysis

    Costs and management of patients with hemophilia A in France: the Hemraude study.

    LAURENDEAU C, GOUDEMAND J, TROSSAERT M, POLACK B, VARIN R, GODARD C, HADIM F, DETOURNAY B.

    Eur J Health Econ. ; 2022;23(1):23-32

  • Biometry and database analysis

    Correction to: Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM)

    SHEN J, BOUEE S, ARIS E, EMERY C, BECK EC.

    Infect Dis Ther ; 2022;11(1):263-264

  • Biometry and database analysis

    Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claim database analysis.

    CORTET B, SCHOTT AM, DESAMERICQ G, CHAUNY JV, SAMAMA P, EMERY C, FAGNANI F.

    Bone ; 2022;154:116255

  • Biometry and database analysis

    Non‑tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study

    VEZIRIS N, ANDREJAK C, BOUEE S, EMERY C, OBRADOVIC M, CHIRON R.

    BMC Infectious Diseases ; 2021;21(1):1165

  • Pharmaco - Epidemiology

    Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France.

    ALLANORE Y, CONSTANS J, GODARD D, DE POUVOURVILLE G, BOUEE S, JEANBAT V, TEISSIER C, LE LAY K, CHOLLET J, HACHULLA E.

    J Scleroderma Related Disorders ; 2022;7(1):49-56

  • Pharmaco-Economics

    France’s competitiveness in global pharmaceutical research: The situation is improving

    D’ANDON A, GALAUP A, FABRON C, DETOURNAY B, BOREL T.

    Therapies ; 2021;76(6):549-557

  • Pharmaco-Economics

    Le système de santé français aujourd’hui – Enjeux et défis : Mieux mobiliser l’évaluation économique pour réguler les dépenses de santé.

    BONASTRE J, DETOURNAY B, SERRIER H.

    Revue du Collège des économistes de la santé ; 2021:65-80

  • Biometry and database analysis

    Prevalence and management of chronic nodular prurigo (CNPG) in Brittany (France): estimation by matching two databases.

    MISERY L, BRENAUT E, TORRETON E, BONTE J, BOUEE S.

    Journal of the European Academy of Dermatology and Venereology ; 2021;35(9):e602-e604

  • Biometry and database analysis

    Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database

    TAHA M.-K , WEIL-OLIVIER C , BOUEE S, EMERY C , NACHBAUR G, PRIBIL C, LONCLE-PROVOT V.

    HUMAN VACCINES & IMMUNOTHERAPEUTICS ; 2021;17(6):1858-1866

  • Biometry and database analysis

    Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database

    WEIL-OLIVIER C, TAHA M-K, EMERY C, BOUEE S, BECK E, ARIS E, LONCLE-PROVOT V, NACHBAUR G, PRIBIL C.

    Infectious Diseases and Therapy ; 2021;10:1607–1623

  • Pharmaco-Economics

    Conséquences économiques du non-respect des règles d’arrêt des agonistes des récepteurs du GLP-1 au moment du passage à l’insuline en France

    DETOURNAY B, SAFSAF, S, BAHLOUL A, CHARBONNEL B.

    Med Mal Metab ; 2021;15(5):537-541

  • Biometry and database analysis

    Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

    GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C

    Future Oncol ; 2020;16(16),1115-1124